Quest Diagnostics, Inc’s recent filing unveils that its SVP & Chief Commercial Officer DELANEY MARK E unloaded Company’s shares for reported $0.15 million on May 12 ’25. In the deal valued at $175.72 per share,874 shares were sold. As a result of this transaction, DELANEY MARK E now holds 8,372 shares worth roughly $1.52 million.
Then, DELANEY MARK E sold 874 shares, generating $153,221 in total proceeds. Upon selling the shares at $175.31, the SVP & Chief Commercial Officer now owns 7,498 shares.
Before that, DELANEY MARK E bought 874 shares. Quest Diagnostics, Inc shares valued at $153,221 were divested by the Officer at a price of $175.31 per share.
Redburn Atlantic initiated its Quest Diagnostics, Inc [DGX] rating to a Buy in a research note published on April 02, 2025; the price target was $195. A number of analysts have revised their coverage, including Citigroup’s analysts, who decreased its forecast for the stock in early March from “a Buy” to “a Neutral”. Leerink Partners also remained covering DGX and has increased its forecast on January 06, 2025 with a “an Outperform” recommendation from previously “Market perform” rating. Morgan Stanley revised its rating on December 17, 2024. It rated DGX as “an Overweight” which previously was an “an Equal-weight”.
Price Performance Review of DGX
On Monday, Quest Diagnostics, Inc [NYSE:DGX] saw its stock jump 1.03% to $182.07. Over the last five days, the stock has gained 3.51%. Quest Diagnostics, Inc shares have risen nearly 20.69% since the year began. Nevertheless, the stocks have risen 31.15% over the past one year. While a 52-week high of $181.90 was reached on 06/16/25, a 52-week low of $135.47 was recorded on 01/16/25.
Levels Of Support And Resistance For DGX Stock
The 24-hour chart illustrates a support level at 180.06, which if violated will result in even more drops to 178.05. On the upside, there is a resistance level at 183.23. A further resistance level may holdings at 184.38.
